Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: A retrospective, outcomes-based survey

Current Oncology

Volumn 17, Issue 4, 2010, Pages 42-47

  Saibil, S ^a   Fitzgerald, B ^a   Freedman, O C ^b   Amir, E ^c   Napolskikh, J ^d   Salvo, N ^a   Dranitsaris, G ^a   Clemons, M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Durham Regional Cancer Centre   (Canada)

^c Health Economics and Biostatistics   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Anthracyclines; Breast cancer; Taxanes; Toxicities

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; NARCOTIC AGENT; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; BRIEF PAIN INVENTORY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; DISTRESS SYNDROME; FEMALE; HEADACHE; HEALTH SURVEY; HUMAN; LEG PAIN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MYALGIA; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RETROSPECTIVE STUDY; THORAX PAIN;

EID: 78149434860     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i4.562     Document Type: Article

References (12)

1. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
2. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27.
3. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
4. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the fnclcc pacs 01 Trial. J Clin Oncol 2006;24:5664-71.
5. Markman M. Managing taxane toxicities. Support Care Cancer 2003;11:144-7.
6. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from nsabp B-28. J Clin Oncol 2005;23:3686-96.
7. Slamon D, Eiermann W, Robert N, et al. Phase iii randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ac→t) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ac→th) with docetaxel, carboplatin and trastuzumab (tch) in her2neu positive early breast cancer patients: bcirg 006 study [abstract 62]. San Antonio, TX: San Antonio Breast Cancer Symposium; 2009. [Available online at: www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1752; cited May 11, 2010].
8. Smith RE, Anderson SJ, Brown A, et al. Phase ii trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from nsabp trial BP-58. Clin Breast Cancer 2002;3:333-40.
9. Jones SE, Savin MA, Holmes FA, et al. Phase iii trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7.
10. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 1996;67:267-73.
11. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994;30A:1326-36.
12. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy-Taxane (fact- Taxane). Cancer 2003;98:822-31.